Showing results (171-180 of 351) with videos related to

Sort By:
Pageof 36
The American Journal of Gastroenterology|March 6, 2009
Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trialsF Keus, J Wetterslev, C Gluud, et al.
Acta Anaesthesiologica Scandinavica|May 26, 2018
Systematic overview and critical appraisal of meta-analyses of interventions in intensive care medicineT M Koster, J Wetterslev, C Gluud, et al.
The Journal of Antimicrobial Chemotherapy|May 30, 2009
Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trialC M Jespersen, H J Kolmos, N Frydendall, et al.
Haematologica|March 20, 2001
Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipientsG Dotti, F Gaspari, R Caruso, et al.
Cell Death and Differentiation|May 9, 2000
Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspasesM Gianni, I Ponzanelli, L Mologni, et al.
Leukemia & Lymphoma|May 7, 1998
The role of idarubicin in adult acute lymphoblastic leukaemia: from drug resistance studies to clinical applicationR Bassan, B Chiodini, T Lerede, et al.
Bone Marrow Transplantation|September 19, 2006
Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantationM Introna, M Franceschetti, A Ciocca, et al.
Blood|April 16, 1998
Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantationA Rambaldi, G Borleri, G Dotti, et al.
Blood|April 1, 1989
Differences in the expression of alkaline phosphatase mRNA in chronic myelogenous leukemia and paroxysmal nocturnal hemoglobinuria polymorphonuclear leukocytesA Rambaldi, M Terao, S Bettoni, et al.
Haematologica|July 11, 1998
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemiaR Bassan, T Lerede, M Buelli, et al.
Pageof 36